FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis

Patrick K. A. Kearns; Sarah J. Martin; Jessie Chang; Rozanna Meijboom; Elizabeth N. York; Yingdi Chen; Christine Weaver; Amy Stenson; Katarzyna Hafezi; Stacey Thomson; Elizabeth Freyer; Lee Murphy; Adil Harroud; Peter Foley; David Hunt; Margaret McLeod; Jonathon O'Riordan; F. J. Carod-Artal; Niall J. J. MacDougall; Sergio E. Baranzini; Adam D. Waldman; Peter Connick; Siddharthan Chandran

doi:10.1136/bmjopen-2021-058506

FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis

Patrick K. A. Kearns (Lead / Corresponding author), Sarah J. Martin, Jessie Chang, Rozanna Meijboom, Elizabeth N. York, Yingdi Chen, Christine Weaver, Amy Stenson, Katarzyna Hafezi, Stacey Thomson, Elizabeth Freyer, Lee Murphy, Adil Harroud, Peter Foley, David Hunt, Margaret McLeod, Jonathon O'Riordan, F. J. Carod-Artal, Niall J. J. MacDougall, Sergio E. BaranziniAdam D. Waldman, Peter Connick, Siddharthan Chandran

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

98 Downloads (Pure)

Abstract

Purpose: Multiple sclerosis (MS) is an immune-mediated, neuroinflammatory disease of the central nervous system and in industrialised countries is the most common cause of progressive neurological disability in working age persons. While treatable, there is substantial interindividual heterogeneity in disease activity and response to treatment. Currently, the ability to predict at diagnosis who will have a benign, intermediate or aggressive disease course is very limited. There is, therefore, a need for integrated predictive tools to inform individualised treatment decision making.

Participants: Established with the aim of addressing this need for individualised predictive tools, FutureMS is a nationally representative, prospective observational cohort study of 440 adults with a new diagnosis of relapsing-remitting MS living in Scotland at the time of diagnosis between May 2016 and March 2019.

Findings to date: The study aims to explore the pathobiology and determinants of disease heterogeneity in MS and combines detailed clinical phenotyping with imaging, genetic and biomarker metrics of disease activity and progression. Recruitment, baseline assessment and follow-up at year 1 is complete. Here, we describe the cohort design and present a profile of the participants at baseline and 1 year of follow-up.

Future plans: A third follow-up wave for the cohort has recently begun at 5 years after first visit and a further wave of follow-up is funded for year 10. Longer-term follow-up is anticipated thereafter.

Original language	English
Article number	e058506
Number of pages	16
Journal	BMJ Open
Volume	12
Issue number	6
DOIs	https://doi.org/10.1136/bmjopen-2021-058506
Publication status	Published - 29 Jun 2022

Keywords

Adult
Biomarkers
Cohort Studies
Disease Progression
Humans
Multiple Sclerosis/diagnosis
Multiple Sclerosis, Relapsing-Remitting/diagnosis
Prospective Studies
neuroradiology
multiple sclerosis
neurogenetics
internal medicine
epidemiology
neurology

ASJC Scopus subject areas

General Medicine

Access to Document

10.1136/bmjopen-2021-058506Licence: CC BY

Final Published VersionFinal published version, 5.56 MBLicence: CC BY

Cite this

Kearns, P. K. A., Martin, S. J., Chang, J., Meijboom, R., York, E. N., Chen, Y., Weaver, C., Stenson, A., Hafezi, K., Thomson, S., Freyer, E., Murphy, L., Harroud, A., Foley, P., Hunt, D., McLeod, M., O'Riordan, J., Carod-Artal, F. J., MacDougall, N. J. J., ... Chandran, S. (2022). FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis. BMJ Open, 12(6), Article e058506. https://doi.org/10.1136/bmjopen-2021-058506

@article{31af44b193af4c31ba82f9c1f76dd0cf,

title = "FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis",

abstract = "Purpose: Multiple sclerosis (MS) is an immune-mediated, neuroinflammatory disease of the central nervous system and in industrialised countries is the most common cause of progressive neurological disability in working age persons. While treatable, there is substantial interindividual heterogeneity in disease activity and response to treatment. Currently, the ability to predict at diagnosis who will have a benign, intermediate or aggressive disease course is very limited. There is, therefore, a need for integrated predictive tools to inform individualised treatment decision making.Participants: Established with the aim of addressing this need for individualised predictive tools, FutureMS is a nationally representative, prospective observational cohort study of 440 adults with a new diagnosis of relapsing-remitting MS living in Scotland at the time of diagnosis between May 2016 and March 2019.Findings to date: The study aims to explore the pathobiology and determinants of disease heterogeneity in MS and combines detailed clinical phenotyping with imaging, genetic and biomarker metrics of disease activity and progression. Recruitment, baseline assessment and follow-up at year 1 is complete. Here, we describe the cohort design and present a profile of the participants at baseline and 1 year of follow-up.Future plans: A third follow-up wave for the cohort has recently begun at 5 years after first visit and a further wave of follow-up is funded for year 10. Longer-term follow-up is anticipated thereafter.",

keywords = "Adult, Biomarkers, Cohort Studies, Disease Progression, Humans, Multiple Sclerosis/diagnosis, Multiple Sclerosis, Relapsing-Remitting/diagnosis, Prospective Studies, neuroradiology, multiple sclerosis, neurogenetics, internal medicine, epidemiology, neurology",

author = "Kearns, {Patrick K. A.} and Martin, {Sarah J.} and Jessie Chang and Rozanna Meijboom and York, {Elizabeth N.} and Yingdi Chen and Christine Weaver and Amy Stenson and Katarzyna Hafezi and Stacey Thomson and Elizabeth Freyer and Lee Murphy and Adil Harroud and Peter Foley and David Hunt and Margaret McLeod and Jonathon O'Riordan and Carod-Artal, {F. J.} and MacDougall, {Niall J. J.} and Baranzini, {Sergio E.} and Waldman, {Adam D.} and Peter Connick and Siddharthan Chandran",

note = "Funding Information: FutureMS has been funded by Precision Medicine Scotland Innovation Centre (PMS_IC: R44346 & R44800), the Rowling Clinic, and Biogen Idec. Insurance provided by the Co-Sponsors: NHS Lothian and the University of Edinburgh. {\textcopyright} Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.",

year = "2022",

month = jun,

day = "29",

doi = "10.1136/bmjopen-2021-058506",

language = "English",

volume = "12",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "6",

}

Kearns, PKA, Martin, SJ, Chang, J, Meijboom, R, York, EN, Chen, Y, Weaver, C, Stenson, A, Hafezi, K, Thomson, S, Freyer, E, Murphy, L, Harroud, A, Foley, P, Hunt, D, McLeod, M, O'Riordan, J, Carod-Artal, FJ, MacDougall, NJJ, Baranzini, SE, Waldman, AD, Connick, P & Chandran, S 2022, 'FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis', BMJ Open, vol. 12, no. 6, e058506. https://doi.org/10.1136/bmjopen-2021-058506

TY - JOUR

T1 - FutureMS cohort profile

T2 - a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis

AU - Kearns, Patrick K. A.

AU - Martin, Sarah J.

AU - Chang, Jessie

AU - Meijboom, Rozanna

AU - York, Elizabeth N.

AU - Chen, Yingdi

AU - Weaver, Christine

AU - Stenson, Amy

AU - Hafezi, Katarzyna

AU - Thomson, Stacey

AU - Freyer, Elizabeth

AU - Murphy, Lee

AU - Harroud, Adil

AU - Foley, Peter

AU - Hunt, David

AU - McLeod, Margaret

AU - O'Riordan, Jonathon

AU - Carod-Artal, F. J.

AU - MacDougall, Niall J. J.

AU - Baranzini, Sergio E.

AU - Waldman, Adam D.

AU - Connick, Peter

AU - Chandran, Siddharthan

N1 - Funding Information: FutureMS has been funded by Precision Medicine Scotland Innovation Centre (PMS_IC: R44346 & R44800), the Rowling Clinic, and Biogen Idec. Insurance provided by the Co-Sponsors: NHS Lothian and the University of Edinburgh. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

PY - 2022/6/29

Y1 - 2022/6/29

N2 - Purpose: Multiple sclerosis (MS) is an immune-mediated, neuroinflammatory disease of the central nervous system and in industrialised countries is the most common cause of progressive neurological disability in working age persons. While treatable, there is substantial interindividual heterogeneity in disease activity and response to treatment. Currently, the ability to predict at diagnosis who will have a benign, intermediate or aggressive disease course is very limited. There is, therefore, a need for integrated predictive tools to inform individualised treatment decision making.Participants: Established with the aim of addressing this need for individualised predictive tools, FutureMS is a nationally representative, prospective observational cohort study of 440 adults with a new diagnosis of relapsing-remitting MS living in Scotland at the time of diagnosis between May 2016 and March 2019.Findings to date: The study aims to explore the pathobiology and determinants of disease heterogeneity in MS and combines detailed clinical phenotyping with imaging, genetic and biomarker metrics of disease activity and progression. Recruitment, baseline assessment and follow-up at year 1 is complete. Here, we describe the cohort design and present a profile of the participants at baseline and 1 year of follow-up.Future plans: A third follow-up wave for the cohort has recently begun at 5 years after first visit and a further wave of follow-up is funded for year 10. Longer-term follow-up is anticipated thereafter.

AB - Purpose: Multiple sclerosis (MS) is an immune-mediated, neuroinflammatory disease of the central nervous system and in industrialised countries is the most common cause of progressive neurological disability in working age persons. While treatable, there is substantial interindividual heterogeneity in disease activity and response to treatment. Currently, the ability to predict at diagnosis who will have a benign, intermediate or aggressive disease course is very limited. There is, therefore, a need for integrated predictive tools to inform individualised treatment decision making.Participants: Established with the aim of addressing this need for individualised predictive tools, FutureMS is a nationally representative, prospective observational cohort study of 440 adults with a new diagnosis of relapsing-remitting MS living in Scotland at the time of diagnosis between May 2016 and March 2019.Findings to date: The study aims to explore the pathobiology and determinants of disease heterogeneity in MS and combines detailed clinical phenotyping with imaging, genetic and biomarker metrics of disease activity and progression. Recruitment, baseline assessment and follow-up at year 1 is complete. Here, we describe the cohort design and present a profile of the participants at baseline and 1 year of follow-up.Future plans: A third follow-up wave for the cohort has recently begun at 5 years after first visit and a further wave of follow-up is funded for year 10. Longer-term follow-up is anticipated thereafter.

KW - Adult

KW - Biomarkers

KW - Cohort Studies

KW - Disease Progression

KW - Humans

KW - Multiple Sclerosis/diagnosis

KW - Multiple Sclerosis, Relapsing-Remitting/diagnosis

KW - Prospective Studies

KW - neuroradiology

KW - multiple sclerosis

KW - neurogenetics

KW - internal medicine

KW - epidemiology

KW - neurology

UR - http://www.scopus.com/inward/record.url?scp=85133147179&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2021-058506

DO - 10.1136/bmjopen-2021-058506

M3 - Article

C2 - 35768080

SN - 2044-6055

VL - 12

JO - BMJ Open

JF - BMJ Open

IS - 6

M1 - e058506

ER -

FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this